In response to a July warning letter from the US Food and Drug Administration, Outset Medical has decided to pause shipments of its TabloCart with Prefiltration (TabloCart) until the company secures 510(k) clearance for marketing authorization, the company announced in second quarter financial results.
Lacking 510(k) clearance for the TabloCart was one of two concerns cited by the FDA in its July letter to the company. (Also see "FDA Sends Warning To Outset...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?